Treatment of disseminated toxoplasmosis/toxoplasma encephalitis with pyrimethamine/sulfadiazine
Phase 2
Recruiting
- Conditions
- Disseminated toxoplasmosis and toxoplasma encephalitis
- Registration Number
- JPRN-jRCTs071180095
- Lead Sponsor
- Maruyama Haruhiko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Confirmed toxoplasmosis patients (DNA positive)
Suspected toxoplasmosis patients
#1 typical brain imaging
#2 serum anti-Toxoplasma IgG positive
#3 other diseases are excluded
Exclusion Criteria
#1 HIV positive patients
#2 patients allergic to test compounds
#3 patients with megaloblastic anemia due to
folate deficiency
#4 No consent is given from the patient
him/herself nor a legally authorized
representative/guardian of the patient
#5 patients principal investigator judged
inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method